Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649670 | 0.96 | P2RX7 (0.48) | F2P2RX7CYP3A4ERCC1ERCC4 | |
| SCHEMBL5652019 | 0.90 | P2RX7 (0.45) | F2P2RX7CYP3A4 | |
| SCHEMBL5650513 | 0.89 | F2 (0.48) | F2P2RX7 | |
| SCHEMBL5646890 | 0.85 | P2RX7 (0.48) | F2P2RX7PRSS1 | |
| Hydrochloric Acid SCHEMBL5649636 | 0.85 | F2 (0.61) | F2P2RX7CYP3A4PRSS1 | |
| SCHEMBL5651491 | 0.84 | F2 (0.47) | F2P2RX7CYP3A4PRSS1 | |
| SCHEMBL5650353 | 0.84 | F2 (0.46) | F2P2RX7CYP3A4PRSS1 | |
| SCHEMBL5651838 | 0.84 | P2RX7 (0.51) | F2P2RX7 | |
| SCHEMBL5648686 | 0.84 | F2 (0.47) | F2P2RX7CYP3A4PRSS1 | |
| SCHEMBL5645368 | 0.83 | P2RX7 (0.48) | F2P2RX7CYP3A4PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| CN-1918124-A | New pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | F2 2/4885P2RX7 2777/4885CYP3A4 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.